We license, develop and commercialize novel tech solutions to improve living gluten-free.
Glutenostics is dedicated to improving the diagnosis and life-long management of celiac disease, gluten sensitivity/intolerance and other gluten-related disorders.
Through the licensing, development and commercialization of novel technologies, Glutenostics is bringing new tools to market that address the unmet needs of millions of Americans avoiding gluten for health concerns.
Glutenostics was formed by an experienced biotech management team in 2016, recognizing the struggle for celiac patients in maintaining strict adherence to the gluten-free diet. Half or more of patients fail to properly adhere to the diet, putting them at risk of health complications and highlighting the need for better tests and tools to manage their health.
The company in-licensed its first technology from Biomedal (Seville, Spain) for rapid, at-home urine & stool monitoring of gluten for assessing compliance with the gluten-free diet, and launched the product (Gluten Detective) to the US market in November 2017 (Visit GlutenDetective.com).
Glutenostics continues to strive to fulfill its mission by evaluating, licensing and/or developing additional technologies to improve the ability to live and thrive gluten-free.
Glutenostics highly values science, integrity and relationships above all else. In staying true to these values, Glutenostics is committed to thoroughly validating its technologies and gaining the support of the scientific and medical community to promote adoption of its technologies. To that end, Glutenostics has partnered with major research, diagnostic and medical treatment centers throughout the USA.
In addition to its advisory board consisting of the top medical leaders in celiac disease, the company has partnered with a dozen notable centers to support research and another 50+ medical centers with more to come, to advocate and disseminate these novel technologies to patients in need.